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OBJECTIVES To determine the effect of angiotensin-converting enzyme (ACE) inhibition on brachial
flow-mediated vasodilation.
BACKGROUND Quinapril, an ACE inhibitor with high affinity, has been shown to improve coronary
endothelial dysfunction in patients with coronary artery disease. The effectiveness of different
vasoactive agents to improve human endothelial function is unknown.
METHODS High resolution ultrasound was used to assess endothelium-dependent brachial artery
flow-mediated vasodilation (FMD) in patients with coronary disease. We studied 80 patients
(mean age 58 6 0.9 years) in a partial-block, cross-over design trial. Patients were
randomized to one of four different drug sequences to receive quinapril 20 mg, enalapril
10 mg, losartan 50 mg or amlodipine 5 mg daily. Each patient received three drugs with a
two-week washout period between treatments. The primary end point was the absolute
difference in FMD after eight weeks of each study drug compared with their respective
baselines analyzed in a blinded fashion.
RESULTS There was mild impairment of FMD at baseline (7.3 6 0.6%). The change in FMD from
baseline was significant only for quinapril (1.8 6 1%, p , 0.02). No change was seen with
losartan (0.8 6 1.1%, p 5 0.57), amlodipine (0.3 6 0.9%, p 5 0.97) or enalapril (20.2 6
0.8%, p 5 0.84). No significant change in nitroglycerin-induced dilation occurred with drug
therapy. The improvement in quinapril response was not seen in those with the DD ACE
genotype (0.5 6 2.1%) but was seen in those with the ID and II genotype (3.3 6 1.2 and
3.2 6 1.9%, respectively, p 5 0.03).
CONCLUSION Only quinapril was associated with significant improvement in FMD, and this response is
related to the presence of the insertion allele of the ACE genotype. (J Am Coll Cardiol 2000;
35:60–6) © 1999 by the American College of Cardiology
Angiotensin-converting enzyme (ACE) inhibitors have
been shown to be highly effective against a variety of
cardiovascular disorders (1). A functional ACE system
present in the vascular endothelium contributes to the
regulation of vascular tone (2). The healthy endothelium
releases autocrine and paracrine factors such as nitric oxide
(NO) which maintain vascular integrity (3). Endothelial
dysfunction occurs early in the course of atherosclerosis in
response to cardiovascular risk factors (4,5) and contributes
to the morbidity of coronary disease.
Angiotensin-converting enzyme inhibition has a favor-
able effect on endothelial function in animal models (6).
Studies have suggested that bradykinin is the mediator
responsible for the beneficial effects of ACE inhibition on
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endothelial function and atherosclerosis development (7,8).
However, angiotensin II blockers, agents that have no effect
on bradykinin, have demonstrated beneficial vascular effects
comparable to ACE inhibitors in some studies (9,10).
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Recently, six months of therapy with the tissue-specific
ACE inhibitor, quinapril, has been shown to improve
coronary endothelium-dependent vasodilation in patients
with coronary atherosclerosis (11). The effect of angiotensin
II blockade on endothelial function has not been studied in
humans. In addition, the ACE gene I/D polymorphism is
well described, and the deletion genotype has been associ-
ated with higher levels of circulating ACE. Some studies
have suggested that the effects of ACE inhibition differ
according to this gene polymorphism.
The present study was designed to compare the effect of
ACE inhibition with quinapril or enalapril, angiotensin II
blockade with losartan, and calcium-channel blocking ther-
apy with amlodipine on brachial artery endothelial function
in patients with coronary artery disease. Amlodopine is an
anti-hypertensive drug without significant effect on the
angiotensin system, but it may have favorable effects on the
endothelium in vitro (12). In addition, we sought to study
the relationship between the ACE genotype and the change
in vasomotor responses with drug therapy.
METHODS AND ANALYSIS
Patient population. The study population consisted of 80
patients recruited from the University of Calgary and
McGill University. Patients were eligible for the study if
they had at least one .50% stenosis in a major vessel
verified by angiography within the preceding six months.
Patients were excluded for the following reasons: history of
coronary bypass grafting, myocardial infarction within 28
days, left ventricular dysfunction (ejection fraction ,40%),
total cholesterol .6 mmol/liter, uncontrolled hypertension
(.160/95), significant valvular heart disease, type I diabetes
mellitus or smoking within six months before screening.
Patients were excluded if they had received ACE inhibition,
angiotensin II blockade or treatment with dihydropyridines
within six months of randomization. Also, treatment with
lipid-lowering agents, hormone replacement therapy or
antioxidant therapy within three months of randomization
was an exclusion. Most patients received aspirin (95%), and
some were taking long-acting nitrates (36%).
Study protocol. RANDOMIZATION. Written, informed
consent was obtained at both institutions in accordance with
the guidelines established by the Committee for the Pro-
tection of Human Subjects. Subjects were randomized to
one of four treatment groups according to a randomization
code card. Patients received three study drugs for eight
weeks each with a two-week washout period between each,
in a crossover design. Patients were randomized to groups 1
and 2 on a 2:1 basis versus groups 3 and 4. The four groups
were as follows: Group 1: quinapril, enalapril, losartan (n 5
25); Group 2: enalapril, quinapril, amlodipine (n 5 28);
Group 3: losartan, amlodipine, quinapril (n 5 13); Group 4:
amlodipine, losartan, enalapril (n 5 14). The study medi-
cation was open-label and consisted of quinapril 20 mg,
enalapril 10 mg, losartan 50 mg, and amlodipine 5 mg each
taken daily.
BRACHIAL ENDOTHELIAL FUNCTION STUDIES. Assessment
of brachial artery endothelial function was performed at
baseline, after each eight-week study period and at the end
of each washout period (six studies) by a previously validated
technique (13,14). A 7.5 MHz linear phase arrayed ultra-
sound transducer attached to a Hewlett-Packard ultrasound
machine was used. Pulsed wave doppler was used to record
brachial artery velocity for each of the interventions. The
study medications were withdrawn 72 6 12 h before
brachial studies, and vasoactive calcium-channel blockers
and nitrates were discontinued at least 12 h before the
brachial studies.
ACE GENOTYPING. A separate informed consent was ob-
tained from each participant, and DNA was isolated from
peripheral blood lymphocytes as previously described (15).
The polymerase chain reaction was performed using a
modified method of Rigat et al. (16). Reactions were
performed using 1.0 to 1.7 mg of template DNA, 25 pmol of
each primer and five units of TAQ polymerase (Pharmacia).
Data analysis. BRACHIAL ARTERY ANALYSIS. Brachial ar-
tery analysis was performed at a core laboratory at the
University of Calgary by a single technician blinded to the
study group assignment or study sequence. Three sequential
systolic frames (taken at the end of the T wave on the
electrocardiogram) for each were digitized via an analog to
digital converting board. A software algorithm automati-
cally calculates the average diameter (100 points) over the
operator-selected segment. Flow-mediated vasodilation
(FMD) was calculated from the diameters as: (reactive
hyperemia 2 baseline)/baseline 3 100%. The intra- and
interobserver variability in our laboratory is 1%. Systolic
frames were used as previously validated (13). In 20 studies
selected randomly, measurements were made at both end-
diastole and systole, and the FMD was exactly the same. In
addition, to normalize for changes in nitroglycerin (NTG)
effect, a normalized ratio was calculated as reactive hyper-
emia diameter/NTG diameter. The percentage change in
this ratio from baseline to eight-week study was determined.
Brachial artery flow was calculated as the product of velocity
and cross-sectional arterial area.
STATISTICS. All data presented are mean 6 standard error
of the mean. The primary efficacy parameter, change from
baseline in flow-mediated brachial artery vasodilation, was
compared among the four treatments by analysis of covari-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANCOVA 5 analysis of covariance
FMD 5 flow-mediated vasodilation
NO 5 nitric oxide
NTG 5 nitroglycerin
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ance (ANCOVA) (17). The study was powered to be able to
detect a difference of 2% (SD 4%) between the quinapril and
enalapril treatment groups. Change from baseline in FMD
was compared among the four treatment groups using
ANCOVA. The SAS 6.08 procedure GLM was used to
generate the analysis. Adjusted means for each treatment
group were generated by the procedure. The adjusted means
were compared to baseline or zero change using t tests. The
variance from the ANCOVA model was used. The
ANCOVA model included study site, treatment sequence,
subject, period and treatment. The baseline measure was
included as a covariate. No adjustments to alpha level were
made, as these were the pre-specified comparisons. When
comparisons were made between treatments, the Bonferroni
method was used to preserve the experiment-wide alpha
level of 0.05. Demographic data among the four groups
were compared by analysis of variance, and changes during
the study period among parameters (blood pressure) were
examined by repeated measures.
RESULTS
Patient demographics and events. The study population
consisted of 80 patients with coronary artery disease. Com-
plete brachial ultrasound data were available from 194
treatment periods (of a possible 240). In total, 17 patients
withdrew before completion of the study (six for adverse
events). There was no difference in the demographics
compared with those patients completing the study. Base-
line demographic parameters between different randomiza-
tion groups were well-matched (Table 1). The mean age of
the study population was 58 6 0.9 years, with 82% male.
Risk factors were present as follows: hypercholesterolemia
54%, hypertension 26% and diabetes mellitus 10%. Previous
myocardial infarction was present in 47%, and 95% had
previous angioplasty. There was no change in serum lipids
during any of the treatment periods from baseline values:
total cholesterol 5.1 6 0.1, low-density lipoprotein choles-
terol 3.1 6 0.1, high-density lipoprotein cholesterol 1.1 6
0.1, or triglycerides 2.2 6 0.1 (mmol/liter). There was no
significant change in blood pressure during any of the
treatment periods, but the measurements were made 72 h
after drug withdrawal (Table 2). The mean blood pressure at
entry was 125/75 mm Hg.
During the course of the study there were no deaths, and
there were 17 hospitalizations for chest pain. The frequency
of reported hospitalizations and angina was similar for the
four treatments. The only associated adverse event more
prevalent in specific treatment groups was “increased cough”
noted more commonly with both ACE inhibitors.
Treatment effect on brachial artery characteristics. Flow-
mediated vasodilation is inversely related to baseline bra-
chial artery diameter in this and other studies (4). The
baseline brachial artery diameter was the same for each of
the drugs tested, and the study medications, despite being
Table 1. Baseline Demographics
Group 1
(n 5 25)
Group 2
(n 5 28)
Group 3
(n 5 13)
Group 4
(n 5 14)
Age 60 6 2 57 6 1 59 6 2 57 6 2
Male (%) 21 (84) 23 (82) 12 (92) 10 (71)
Female (%) 4 (16) 5 (18) 1 (8) 4 (29)
Myocardial infarction 7 (28) 16 (57) 9 (69) 5 (36)
Hypertension 9 (36) 5 (18) 2 (15) 5 (36)
Diabetes mellitus 4 (17) 3 (10) 1 (8) 1 (7)
Lipids (mmol/liter)
Total cholesterol 4.9 6 0.1 5.2 6 0.2 5.0 6 0.3 5.3 6 0.1
HDL-C 1.1 6 0.05 1.0 6 0.04 1.0 6 0.1 1.1 6 0.1
LDL-C 2.9 6 0.1 3.2 6 0.2 3.1 6 0.2 3.3 6 0.2
Triglycerides 2.1 6 0.2 2.2 6 0.2 2.0 6 0.3 2.1 6 0.3
HDL 5 high-density lipoprotein cholesterol; LDL 5 low-density lipoprotein cholesterol. To convert mmol/liters to mg/dl
multiply cholesterol values by 38.67, and triglycerides by 88.57.
Table 2. Baseline Parameters at Initial and Eight Week Study
Baseline
Dia (mm)
Pre
Baseline
Dia (mm)
Post
Delta in
Systolic BP
(mm Hg)
Delta in
Diastolic BP
(mm Hg)
Quinapril (n 5 56) 3.9 6 0.1 3.8 6 0.1 3 6 3 4 6 2
Enalapril (n 5 55) 3.8 6 0.1 3.9 6 0.1 2 6 2 0 6 2
Losartan (n 5 38) 4.0 6 0.1 3.8 6 0.1 3 6 3 2 6 2
Amlodipine (n 5 45) 3.8 6 0.1 3.8 6 0.1 22 6 3 0 6 2
Pre 5 before initiation of medication; Post 5 following eight weeks of study medication (off medications for 72 h).
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vasodilators, had no significant effect on baseline brachial
diameter after eight weeks of therapy (Table 2). Upper arm
occlusion resulted in an increase in forearm blood flow of
approximately 500%, which was the same at baseline for
each drug and was not affected by drug treatment.
Treatment effect on FMD. At baseline, the study popu-
lation had FMD of 7.3 6 0.6% and NTG-mediated
dilation of 14.2 6 0.8%. Baseline FMD and NTG-
mediated vasodilation was the same for each of the drugs
tested. Only treatment with quinapril resulted in a signifi-
cant increase in FMD from baseline (delta 1.8 6 1.0%; p ,
0.02) (Fig. 1). The improvement in FMD was no longer
evident when baseline measurements were repeated after
two weeks of quinapril withdrawal. As a secondary assess-
ment, quinapril’s effects on FMD were compared with the
other four treatments. There was only a trend for a differ-
ence in quinapril compared with enalapril (p 5 0.12) and no
difference when compared with losartan or amlodipine.
There was no significant effect of treatment on NTG-
induced vasodilation. Since there was a trend (p 5 0.10) for
improvement in the NTG response after quinapril, the
FMD/NTG ratio was analyzed. This did not change the
results. Only quinapril demonstrated an improvement from
baseline in the FMD/NTG ratio, while the other agents did
not (Fig. 1b). The improvement in this ratio with quinapril
implies improvement in endothelium-dependent vasodila-
tion and not simply vascular smooth muscle responsiveness.
Treatment effect and ACE genotype. There was no dif-
ference in the baseline flow-mediated vasodilation among
the three genotypes. In response to eight weeks of therapy,
there was no improvement in brachial responses noted in
the DD genotype with any of the four agents. Significant
improvement was attributed only to quinapril in the ID
(delta 3.3 6 1.2%) as well as the II genotype (delta 3.2 6
1.9%). The improvement with quinapril in the ID and II
genotypes was significantly different from the quinapril
response in the DD genotype (Fig. 2).
DISCUSSION
The current study demonstrated that eight weeks of
quinapril improves impaired endothelium-dependent FMD
in the brachial circulation of patients with atherosclerotic
risk factors. This was not seen with the other drugs tested,
suggesting that there may be a difference between the ability
of quinapril and the ability of the other drugs to modulate
vascular function.
Current Study
The patients in the present study had endothelial dysfunc-
tion at baseline as a result of coronary disease, as has been
demonstrated in other studies (13). A significant improve-
ment from baseline endothelial dysfunction was seen with
eight weeks of quinapril therapy only. Patients were studied
after the drug had been withdrawn for 72 h, avoiding the
confounding acute hemodynamic effects of the medication
as in other studies (11).
In addition to an improvement in endothelial function
with quinapril, there was a trend for an improvement in
NTG-mediated vasodilation. Because measurements were
Figure 1. A, The absolute change in percent FMD following
therapy compares with pretreatment baseline values. Only
quinapril resulted in a significant improvement in brachial flow-
mediated vasodilation (*p , 0.02). B, The absolute change in the
ratio of percent FMD/nitroglycerin-induced vasodilation follow-
ing therapy compared with baseline values. Again only quinapril
resulted in significant improvement (*p 5 0.03).
Figure 2. The absolute change in percent FMD following therapy
compares with pretreatment baseline values for quinapril and
enalapril based on ACE genotype. Significant improvement in
FMD seen only in the quinapril group for the ID and II genotype
(*p 5 0.03).
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made during systolic frames, a beneficial effect of quinapril
on vascular smooth muscle (compliance) cannot be ex-
cluded. Interestingly, a corresponding improvement in
NTG-mediated vasodilation was not observed with enala-
pril. Angiotensin-converting enzyme inhibition in hyper-
tensive patients has been previously shown to have a
beneficial effect on the arterial wall morphology of resistance
vessels, although this effect probably takes longer than eight
weeks (18). However, after correcting for changes in NTG
response, the FMD was still augmented, demonstrating an
endothelial effect.
Endothelial Function and ACE-inhibition
Angiotensin converting enzyme–inhibition is thought to
improve vascular function by several mechanisms. It de-
creases the concentration of angiotensin II and hence
endothelin, increases the concentration of bradykinin,
which is a vasodilator and stimulator of NO, endothelial
derived hyperpolarizing factor and prostacyclin, and decreases
superoxide anion concentration (19). An augmentation of
endothelium-dependent vasodilation has been demonstrated
for several ACE inhibitors in animal studies (20). In the
recently published TREND (Trial on Reversing Endothelial
Dysfunction) study, six months of therapy with quinapril
(40 mg/day) attenuated acetylcholine-induced vasoconstriction
in patients with coronary disease (11). Hornig et al. (21) have
recently demonstrated that the acute arterial administration of
quinaprilat augmented brachial FMD, and that this effect is
predominantly mediated via the bradykinin-2 receptor. Animal
studies had also suggested that the beneficial vascular effect of
ACE inhibition was mediated through bradykinin and NO
(22).
It is not clear from the present study why augmentation
of FMD was seen with quinapril but not enalapril. Al-
though the improvement from baseline was not statistically
different among the drugs tested, only quinapril showed a
difference from baseline, and there was a trend for a
difference between the two ACE inhibitors (p 5 0.12). The
lack of effect of enalapril, losartan and amlodipine may be
related to choice of dose or length of treatment. However,
quinapril has been shown to have high tissue specificity for
ACE, and the dissociation of the drug from the enzyme is
markedly prolonged compared with other converting en-
zyme inhibitors (23). In addition, the enhanced lipophilicity
of the drug may allow better cellular penetration with
beneficial effects on enzymatic processes such as cNOS
activity, for example (24). Greater inhibition of vascular
ACE has also been demonstrated for quinapril compared
with enalapril in a recent human study of forearm blood
flow (25). A more recent study by Hornig et al. (26)
demonstrated improved FMD acutely in response to
quinaprilat but not to increasing doses of enalaprilat in
patients with heart failure. Studies of enalapril in diabetics
with endothelial dysfunction have shown mixed results. One
month of treatment with enalapril was able to improve
forearm blood flow in response to acetylcholine in patients
with type I diabetes (27), whereas 24 weeks of enalapril had
no statistically significant effect on FMD in other patients
with type I diabetes (28). Further work is required to
contrast the effects of different ACE inhibitors on vascular
function in different disease states.
Endothelial Function and ACE Genotype
Polymorphism of the ACE gene has been demonstrated,
and the presence of the deletion allele has been associated
with higher levels of circulating and tissue ACE (29). The
DD genotype has also been associated with increased risk of
coronary restenosis and myocardial infarction in some but
not all studies (30,31). In addition, some studies have
suggested a relationship between the genotype and physio-
logical effects from ACE inhibition with attenuation of
beneficial effect noted with the deletion allele (32). In the
present study we noted no difference in baseline brachial
FMD between the different genotypes, as was seen in one
other study (33). However, the improvement in FMD with
quinapril was restricted to the ID and II genotypes. The
reason for this observation is not explained by this study. It
may relate to increased tissue levels of ACE, attenuated
interaction with quinapril and the tissue ACE, or increased
levels of oxidative stress in these subjects. Down-regulation
of the AT1 receptor in those with the DD genotype has also
been recently suggested (34). The duration of effect of ACE
inhibitors may also be related to the genotype, affecting the
results seen (35).
Endothelial Function and Angiotensin-II Blockade
Farhy and colleagues (36) demonstrated that both ramipril
and losartan reduced neointimal proliferation in a rat
balloon injured model, but that ramipril was more effective.
Concomitant bradykinin blockade with HOE-140 nullified
this advantage, suggesting that kinins were important in the
beneficial effect of ramipril in this model. However, a
similarly designed study in rabbits comparing perindopril
and losartan demonstrated equal efficacy in reducing neo-
intimal formation (10).
This is the first human study to assess endothelial
function with an angiotensin-II receptor blocker in
humans. Although there was no difference in the re-
sponse between quinapril and losartan, losartan did not
augment FMD from baseline in our study. Although this
might suggest that vasodilator kinins are important in
augmenting endothelium-dependent vasodilation, further
studies are required to clarify the impact of angiotensin-II
blockade on endothelial function (37,38).
Endothelial Function and Calcium-Channel Blockers
Acute administration of calcium-channel blockers has been
shown to block exercise-induced coronary artery vasocon-
striction in patients with hypertension (39). Amlodipine has
been demonstrated to have antioxidant properties in ath-
erosclerotic animal models, but its effect on endothelial
function has not been assessed in humans (40). In addition,
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amlodipine has been recently shown to increase NO pro-
duction from canine microvessels (41). However, amlodip-
ine (2.5 to 5 mg daily for six months) did not improve
reactive hyperemic blood flow in peripheral arteries of
patients with hypertension by contrast to the improvement
observed with a potent ACE inhibitor, temocapril (42).
Study Limitations
The lack of effect of enalapril, losartan and amlodipine may
be related to improper dosage or length of treatment. Full
dose-ranging and time-course studies for each drug would
be required before concluding that these agents have no
effect on endothelial function. Drugs were withdrawn for
72 h before the brachial studies to avoid hemodynamic
effects, and this may have influenced results as well. How-
ever, in the current model, quinapril did demonstrate
improved vasodilator responses.
Other measures of endothelial function, such as adhesion
molecules or platelet function, were not assessed. In addi-
tion, the relationship between endothelial function and
clinical events has yet to be proven.
There is variability in the ultrasound assessment of FMD
in the acquisition, repeatability and measurement of multi-
ple studies per patient. However, previous brachial studies
with a cross-over design had demonstrated the feasibility of
this approach (43).
Finally, the study was open-label. However, the single
technician who analyzed the more than 500 brachial studies
was blinded to randomization and phase of the study.
Conclusions
In a comparative trial of four vasoactive agents, only
quinapril was associated with significant improvement in
FMD in patients with coronary disease, and this response
appeared to be related to the ACE genotype. There may be
differences in vasoactive drugs in their ability to improve
vascular endothelial function, although further dose-ranging
and time-course studies are required.
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